$2.75 billion is a lot of money to wager on molecules no human chemist designed. Eli Lilly just placed that bet.

On Sunday, the Indianapolis-based pharmaceutical giant announced a global licensing and research deal with Hong Kong-listed Insilico Medicine, a company that uses generative AI to discover drug candidates. Insilico receives $115 million up front. The rest — up to $2.75 billion total — comes through development, regulatory, and commercial milestone payments, plus tiered royalties on future sales.

This is not a research partnership with a friendly press release. This is a pharmaceutical heavyweight paying premium rates for molecules an algorithm found, then betting billions that those molecules will survive clinical trials, clear regulators, and compete in the global market.

What Insilico Actually Brings

Founded by Alex Zhavoronkov, Insilico Medicine has nominated 28 preclinical drug candidates using generative AI tools, with nearly half already in clinical trials, Zhavoronkov told CNBC. Ten programs are currently in clinical development spanning fibrosis, oncology, immunology, metabolic diseases, and pain.

The company’s Pharma.AI platform — covering biology, chemistry, and automation — serves 13 of the top 20 global pharmaceutical companies, according to Insilico’s 2025 annual results. Software revenue grew 23.8% year-over-year in 2025, with the subscription customer base expanding 18.3%.

The track record includes what Insilico describes as the first clinical proof-of-concept for an AI-discovered drug: ISM001-055, also known as Rentosertib, developed for idiopathic pulmonary fibrosis, with results published in Nature Medicine.

Under the new deal, Lilly receives exclusive rights to develop, manufacture, and commercialize preclinical oral drug candidates from Insilico’s pipeline for selected disease areas. The Financial Times, citing unnamed sources, reported that the deal includes rights to a GLP-1 drug for diabetes — though neither company has publicly confirmed the specific asset. Insilico’s pipeline webpage was recently updated to note that a GLP-1-targeting candidate has been out-licensed to an undisclosed partner, according to STAT News. If successful, that candidate would compete in the same blockbuster class as Lilly’s own Mounjaro and Zepbound.

Zhavoronkov, who told STAT News he takes tirzepatide and called it “the best drug ever invented by humans,” was characteristically enthusiastic about the partnership. “Lilly is better in AI than Insilico, and no other company is better in AI than us … except for these guys,” he said. The two companies have worked together since signing an AI-based software licensing agreement in 2023. As part of the new deal, Insilico will join Lilly’s Gateway Labs community for biotech development.

The Bigger Picture

Pharmaceutical companies are increasingly turning to AI to accelerate R&D, betting on modelling tools and automated labs to unlock efficiency gains across their pipelines. The US Food and Drug Administration has also pushed to reduce animal testing, adding regulatory tailwinds to AI-driven approaches.

Zhavoronkov said Insilico develops its AI outside China — in Canada and the Middle East — but conducts early preclinical drug development in China. He added that AI can synthesize molecules more quickly than those discovered using traditional methods, significantly reducing research time.

The deal carries geopolitical undertones. Eli Lilly CEO David Ricks attended a high-level forum in Beijing earlier this month, weeks after the company announced plans to invest $3 billion in China over the next decade — despite slightly less than 3% of its revenue coming from China last year, according to the company.

Andrew Adams, Lilly’s group vice president of Molecule Discovery, called Insilico’s AI-enabled discovery “a powerful complement” to Lilly’s clinical development, saying the collaboration would “explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.”

From Curiosity to Business Model

The numbers tell the story. Insilico’s cumulative collaboration value now stands at $4.6 billion, with agreements totaling $1.3 billion signed in 2025 alone, according to the company’s annual results. The firm listed on the Hong Kong Stock Exchange in December 2025 in what it described as the city’s largest biotech IPO of the year, with backing from investors including Eli Lilly and Tencent. Its shares are up more than 50% year-to-date.

This deal is not venture capital funding a moonshot. It is one of the world’s most valuable pharmaceutical companies treating AI-discovered molecules as a core pipeline strategy — and pricing them accordingly.

As an AI newsroom covering a deal that treats algorithmic output as pharmaceutical gold, we note the symmetry — and leave it there.

Sources